These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 30090971)

  • 21. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].
    An LL; Zhao DF; Hou RF; Guan HH; Yan H; Lin YH; Tong CR; Wu T; Liu SY
    Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):911-916. PubMed ID: 38185520
    [No Abstract]   [Full Text] [Related]  

  • 22. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
    Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
    Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia.
    Morley NJ; Marks DI
    Expert Rev Anticancer Ther; 2016; 16(2):159-64. PubMed ID: 26654587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
    Rubinstein JD; O'Brien MM
    Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
    Nakayama H; Ogawa C; Sekimizu M; Fujisaki H; Kosaka Y; Hashimoto H; Saito AM; Horibe K
    Int J Hematol; 2022 Oct; 116(4):612-621. PubMed ID: 35635686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.
    Tvito A; Rowe JM
    Expert Opin Biol Ther; 2017 Dec; 17(12):1557-1564. PubMed ID: 29092647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
    Jabbour E; O'Brien S; Huang X; Thomas D; Rytting M; Sasaki K; Cortes J; Garcia-Manero G; Kadia T; Ravandi F; Pierce S; Kantarjian H
    Am J Hematol; 2015 Mar; 90(3):193-6. PubMed ID: 25407953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Dahl J; Marx K; Jabbour E
    Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
    Kantarjian H; Thomas D; Jorgensen J; Jabbour E; Kebriaei P; Rytting M; York S; Ravandi F; Kwari M; Faderl S; Rios MB; Cortes J; Fayad L; Tarnai R; Wang SA; Champlin R; Advani A; O'Brien S
    Lancet Oncol; 2012 Apr; 13(4):403-11. PubMed ID: 22357140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
    Torrent A; Morgades M; García-Calduch O; de Llano MPQ; Montesinos P; Navarro I; Hernández-Rivas JM; Bárez-García A; González-Campos J; Oiartzabal I; Valero M; Cervera M; Zudaire T; Albors-Ferreiro M; López-Godino O; Gil-Cortés C; Villalón L; Saldaña R; Ribera JM
    Eur J Haematol; 2023 Sep; 111(3):485-490. PubMed ID: 37381686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
    Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
    Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.
    Jabbour E; Advani AS; Stelljes M; Stock W; Liedtke M; Gökbuget N; Martinelli G; O'Brien S; White JL; Wang T; Luisa Paccagnella M; Sleight B; Vandendries E; DeAngelo DJ; Kantarjian HM
    Am J Hematol; 2019 Apr; 94(4):408-416. PubMed ID: 30623490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.
    Uy N; Nadeau M; Stahl M; Zeidan AM
    J Blood Med; 2018; 9():67-74. PubMed ID: 29713210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.
    Jabbour E; Ravandi F; Kebriaei P; Huang X; Short NJ; Thomas D; Sasaki K; Rytting M; Jain N; Konopleva M; Garcia-Manero G; Champlin R; Marin D; Kadia T; Cortes J; Estrov Z; Takahashi K; Patel Y; Khouri MR; Jacob J; Garris R; O'Brien S; Kantarjian H
    JAMA Oncol; 2018 Feb; 4(2):230-234. PubMed ID: 28859185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
    Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
    O'Brien MM; Ji L; Shah NN; Rheingold SR; Bhojwani D; Yuan CM; Xu X; Yi JS; Harris AC; Brown PA; Borowitz MJ; Militano O; Kairalla J; Devidas M; Raetz EA; Gore L; Loh ML
    J Clin Oncol; 2022 Mar; 40(9):956-967. PubMed ID: 35007127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Chen J; Haughey M; Vandendries E; DeAngelo DJ; Kantarjian HM; Ruiz-Garcia A
    Clin Transl Sci; 2021 Jan; 14(1):184-193. PubMed ID: 32812370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia.
    Bertamini L; Nanni J; Marconi G; Abbenante M; Robustelli V; Bacci F; Matti A; Paolini S; Sartor C; Monaco SL; Fontana MC; De Polo S; Cavo M; Curti A; Martinelli G; Papayannidis C
    BMC Cancer; 2018 Nov; 18(1):1117. PubMed ID: 30442119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
    Thota S; Advani A
    Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.